

UNITED THERAPEUTICS CORP

Form 8-K

February 22, 2005

**SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15 (d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): February 22, 2005

United Therapeutics Corporation

(Exact Name of Registrant as Specified in Charter)

|  |                             |  |
|--|-----------------------------|--|
| Delaware   | 000-26301                   | 52-1984749                                 |
| (State or Other<br>Jurisdiction of<br>Incorporation) | (Commission<br>File Number) | (I.R.S. Employer<br>Identification Number) |

|  |            |
|--|------------|
| 1110 Spring Street<br>Silver Spring, MD  | 20910      |
| (Address of Principal Executive Offices) | (Zip Code) |

Registrant's telephone number, including area code:

(301) 608-9292

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 2.02. Results of Operations and Financial Condition.**

On February 22, 2005, United Therapeutics Corporation (the Company ) issued a press release setting forth its earnings for the Company s quarterly fiscal period and year ended December 31, 2004. A copy of this press release is attached hereto as Exhibit 99.1. The Company does not intend for Exhibit 99.1 to be incorporated by reference into filings under the Securities Act of 1933 or the Securities Exchange Act of 1934.

**Item 9.01. Exhibits**

(c) Exhibits

| <u>Exhibit No.</u> | <u>Description of Exhibit</u>         |
|--------------------|---------------------------------------|
| 99.1               | Press release dated February 22, 2005 |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

UNITED THERAPEUTICS CORPORATION

Dated: February 22, 2005

By: /s/ Paul A. Mahon

Name: Paul A. Mahon

Title: General Counsel

---

EXHIBIT INDEX

| <u>Exhibit No.</u> | <u>Description of Exhibit</u>         |
|--------------------|---------------------------------------|
| 99.1               | Press release dated February 22, 2005 |